Asthma; EosinophilicReNORMNCT07174713
REverse LuNg Airway and Vascular RemOdeling in Asthma ReMission (ReNORM)
A study testing Biologic Therapy in people with Asthma; Eosinophilic, run by Western University, Canada at 1 site in Canada.
Trial summary
In this program of research, the investigators aim to answer the question: In patients with asthma aged 18-80, how do the lung airways and vessels respond to biologic therapy and what role does age and asthma duration have in this response? While about 4.6 million Canadians live with asthma, ~5-10% of patients have… Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Asthma; Eosinophilic
- What is being tested?
- Biologic Therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteCanada
- Study dates
- 1 Oct 2026to Oct 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participants eligible for inclusion in this study must meet all the following criteria:
- Participant understands study procedures and is willing to participate in the study as indicated by the patient's signature.
- Provision of written, informed consent prior to any study specific procedures.
- Males and females aged 18 to 80 years.
- Either diagnosed with severe asthma (GINA Step 5) and newly eligible for biologic therapy (based on ACQ-5, current treatment, exacerbation history, and blood eosinophils in accordance with approved criteria for omalizumab, mepolizumab, benralizumab, dupilumab, or tezepelumab), or a healthy volunteer with no history of chronic lung disease, matched by age and sex. Healthy participants must have a lifetime combustible tobacco and/or cannabis (including vaping) consumption of ≤5 pack-years.
- Women of childbearing potential (after menarche) must ensure that they are using an effective form of birth control for at least 2 months prior to each imaging visit. Examples of effective birth control include:
Show all 17Show fewer
- True sexual abstinence
- A vasectomized sexual partner
- Implanon®
- Female sterilization by tubal occlusion
- Effective intrauterine device (IUD)/levonogestrel intrauterine system (IUS)
- Depo-Provera™ injections
- Oral contraceptive
- Evra Patch™
- Nuvaring™
- Women of childbearing potential (after menarche) must agree to use a highly effective form of birth control, as defined above, from enrollment, throughout the study duration, and 8 weeks after last dose of study drug, with negative urine pregnancy test result at Visit 1-5.
- Male participants who are sexually active must agree to use a double barrier method of contraception (male condom with diaphragm or male condom with cervical cap) from the first dose of the study drug until 8 weeks after last dose
Who cannot join
- Participants fulfilling any of the following criteria are not eligible for inclusion in this study:
- Patient has an implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist).
- In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia.
- Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit.
- Participant is unable to perform spirometry or plethysmography maneuvers.
- Participant is unable to perform MRI and CT breath-hold maneuvers.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site
Robarts Research Institute; The University of Western Ontario
London, Ontario, N6A 5B7
Grace Parraga, PhD, 519-931-5265, gparraga@robarts.ca
About this study
In this program of research, the investigators aim to answer the question: In patients with asthma aged 18-80, how do the lung airways and vessels respond to biologic therapy and what role does age and asthma duration have in this response? While about 4.6 million Canadians live with asthma, ~5-10% of patients have severe asthma meaning that multiple inhaled and systemic oral corticosteroid treatments have failed to improve symptoms and exacerbations, leading to lost work and school days and substantially diminished ability to participate in normal life. For such people, the vast majority of whom are middle aged and remember asthma as part of their entire lifespan, biologic immunomodulator therapies, which block the function of asthma inflammatory pathways, provide a final step-up therapy option. There is emerging evidence that prescribed in the right patient at the right time, the right biologic can result in clinical remission of asthma. While spontaneous clinical remission of asthma is rare, it has been documented in children in whom lung growth and remodeling is still possible. It remains unknown whether clinical remission in adults is accompanied by the reversal of pathologic remodeling, at the level of the airways and pulmonary vessels. This is critical to elucidate as investigators and physicians move forward with currently proposed criteria for "complete asthma remission". The inconvenient truth about asthma and age is that in older adult lungs, exposed to years of infection, exacerbations, smooth muscle remodeling and pulmonary vascular shunt, the mechanisms by which complete pathologic remission may be achieved are complex and poorly understood.
To address this knowledge gap, the investigators will evaluate 150 patients (Vancouver, Ottawa, Hamilton, London) (in three age tertiles 18-29; 30-59; 60-80) with severe asthma and 50 age- and sex matched healthy volunteers over 2-years using chest CT, MRI and pulmonary function tests. The investigators will use the pulmonary imaging measurements to generate an imaging-index of normal airway structure and function which will be compared with and significantly correlate with MR-guided bronchoscopic sample measurements made before and after 1-/2-years of treatment. The investigators will reveal the pathobiologic relationship between age, asthma duration, clinical remission and imaging normalization with direct comparison to histology-based airway measurements.
- Conditions
- Asthma; Eosinophilic
- Being tested
- Biologic Therapy
- Keywords
- Hyperpolarized Xenon MRI, Clinical Remission, Biologic Therapy, Airway Remodeling
- Medical subject headings
- Pulmonary Eosinophilia, Airway Remodeling
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Biologic TherapyBiological
Participants with severe asthma (GINA 5) who are eligible to begin biologic therapy. Participants will undergo serial assessment with pulmonary imaging (CT, MRI), lung function testing, sputum collection, and symptom questionnaires. A subset of participants (~15%) will be randomized to undergo MRI-guided bronchoscopy with airway sampling at baseline and 2 years.
| Study group | Role | What they receive |
|---|---|---|
| Asthma - Biologic Therapy | Experimental | Participants with severe asthma (GINA 5) who are eligible to begin biologic therapy. Participants will undergo serial assessment with pulmonary imaging (CT, MRI), lung function testing, sputum collection, and symptom questionnaires. A subset of participants (~15%) will be randomized to undergo MRI-guided bronchoscopy with airway sampling at baseline and 2 years. Receives: Biological: Biologic Therapy |
| Healthy Control | No intervention | Age- and sex-matched healthy participants with no history of lung disease. Participants will undergo pulmonary imaging (CT, MRI) and lung function testing at baseline and follow-up for comparison with the asthma group. No therapeutic intervention will be provided. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Determine extent of imaging-based remission in patients with severe asthma following 1 and 2 years of biologic therapy
Measured using 129Xe ventilation defect percent (VDP)
Measured: from baseline to year 1 and year 2
Measure the extent and timing of clinical remission in patients with severe asthma as measured by changes in spirometry measurements of FEV1 and FVC
Measured using forced expiratory volume in 1 second and forced vital capacity
Measured: from baseline to 1 year and 2 years
To determine the extent and timing of clinical remission in patients with severe asthma using symptoms scores of ACQ-5 and ACT
Measured using changes in asthma control questionnaire and asthma control test
Measured: From baseline to 1 year and 2 years
Determine the extent and timing of imaging-based remission in patients with severe asthma using CT airway and vessel morphology
Measured using computed tomography (CT) airway and vessel metrics
Measured: From baseline to 1 year and 2 years
To determine the extent and timing of clinical remission using the clinical outcome of frequency of asthma exacerbations in patients with severe asthma
Measured using the number of asthma exacerbations
Measured: from baseline to 1 year and 2 years
To determine the extent and timing of clinical remission of patients with severe asthma using the clinical outcome of OCS use
Measured by the frequency of oral corticosteroid usage
Measured: From baseline to 1 year and 2 years
Determine the extent and timing of clinical remission in patients with severe asthma as measured by sputum and blood eosinophil counts
Measured using blood and sputum eosinophil counts
Measured: From baseline to 1 year and 2 years
Secondary outcomes (17)
Timing and proportion of patients achieving clinical remission after biologic treatment as measured by FEV1 and FVC.
Measured using forced expiratory volume at 1 second and forced vital capacity.
Measured: From baseline to 1 year and 2 years
To determine the timing and proportion of patients achieving clinical remission as measured by ACQ-5 and ACT questionnaires.
Measured by asthma control questionnaire and asthma control test questionnaire scores.
Measured: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving clinical remission after biologic treatment using FeNO.
Measured using fractional exhaled nitric oxide (FeNO)
Measured: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving clinical remission using DLco.
Measured using diffusing capacity of the lung for carbon monoxide (DLco)
Measured: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving clinical remission after biologic treatment using SGRQ score.
Measured using St. George's Respiratory Questionnaire (SGRQ) score.
Measured: From baseline to 1 year and 2 years.
Determine the timing and proportion of patients with severe asthma achieving clinical remission on biologic treatment using AQLQ scores.
Measured using the Asthma Quality of Life Questionnaire (AQLQ) score.
Measured: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using 129-Xe MRI VDP
Measured using the changes in 129-xenon MRI ventilation defect percent (VDP)
Measured: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using CT metrics
Measured using computed tomography (CT) mucus-score, airway dimensions and vascular pruning
Measured: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using DLco.
Measured using diffusing capacity of the lung for carbon monoxide (DLco)
Measured: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using RV/TLC
Measured using the ratio of residual volume to total lung capacity (RV/TLC)
Measured: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using FRC.
Measured using functional residual capacity (FRC).
Measured: From baseline to 1 year and 2 years
Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using changes in VDP
Measured using ventilation defect percent (VDP)
Measured: from baseline to 12-weeks and 2-years
Determine the relationship between clinical and imaging remission and generate predictive models for their achievement using changes in CT.
Measured using computed tomography (CT) airway wall thickness, mucus metrics
Measured: From baseline to 12-weeks and 2-years
Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using FeNO.
Measured using forced exhaled nitric oxide (FeNO).
Measured: From baseline to 12-weeks and 2-years
Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using ACQ-5 and ACT scores.
Measured using asthma control questionnaire and asthma control test scores.
Measured: From baseline to 12-weeks and 2-years.
Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using sputum biomarkers.
Measured using sputum eosinophil and cell count values
Measured: From baseline to 12-weeks and 2-years
Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using exacerbation history.
Measured using patient's reported exacerbation history.
Measured: From baseline to 12-weeks and 2-years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2025
- Study start1 Oct 2026 (estimated)
- Primary completionOct 2030 (estimated)
- Study completionOct 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Asthma; EosinophilicStudies of the same condition, open and under way.
- More trials run by Western University, CanadaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Parallel assignment of participants to one of two arms: (1) patients with severe asthma initiating biologic therapy, and (2) healthy volunteers serving as controls. Asthma patients are followed over 2 years to assess clinical, imaging, and histologic responses to biologic treatment. A randomized subset of asthma participants undergoes MRI-guided bronchoscopy to correlate imaging with histopathology.
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Western University, Canada
- Sponsor type
- University, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Responsible party
- Principal investigator, Dr. Grace Parraga, Western University, Canada
- Investigators
- Grace Parraga, PhD, Principal investigator, Robarts Research Institute, The University of Western Ontario
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07174713
- Sponsor's protocol ID
- ROB0061
- Acronym
- ReNORM
- Status last verified
- Jul 2025
- First submitted
- 8 Aug 2025
- Last updated
- 31 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- REverse LuNg Airway and Vascular RemOdeling in Asthma ReMission (ReNORM)
- ClinicalTrials.gov ID
- NCT07174713
- Acronym / sponsor ID
- ReNORM / ROB0061
- Conditions
- Asthma; Eosinophilic
- Keywords
- Hyperpolarized Xenon MRI, Clinical Remission, Biologic Therapy, Airway Remodeling
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Western University, CanadaUniversity, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- Oct 2030 (estimated)
- Study completion
- Oct 2030 (estimated)
- First posted
- 16 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this program of research, the investigators aim to answer the question: In patients with asthma aged 18-80, how do the lung airways and vessels respond to biologic therapy and what role does age and asthma duration have in this response? While about 4.6 million Canadians live with asthma, ~5-10% of patients have severe asthma meaning that multiple inhaled and systemic oral corticosteroid treatments have failed to improve symptoms and exacerbations, leading to lost work and school days and substantially diminished ability to participate in normal life. For such people, the vast majority of whom are middle aged and remember asthma as part of their entire lifespan, biologic immunomodulator therapies, which block the function of asthma inflammatory pathways, provide a final step-up therapy option. There is emerging evidence that prescribed in the right patient at the right time, the right biologic can result in clinical remission of asthma. While spontaneous clinical remission of asthma is rare, it has been documented in children in whom lung growth and remodeling is still possible. It remains unknown whether clinical remission in adults is accompanied by the reversal of pathologic remodeling, at the level of the airways and pulmonary vessels. This is critical to elucidate as investigators and physicians move forward with currently proposed criteria for "complete asthma remission". The inconvenient truth about asthma and age is that in older adult lungs, exposed to years of infection, exacerbations, smooth muscle remodeling and pulmonary vascular shunt, the mechanisms by which complete pathologic remission may be achieved are complex and poorly understood.
To address this knowledge gap, the investigators will evaluate 150 patients (Vancouver, Ottawa, Hamilton, London) (in three age tertiles 18-29; 30-59; 60-80) with severe asthma and 50 age- and sex matched healthy volunteers over 2-years using chest CT, MRI and pulmonary function tests. The investigators will use the pulmonary imaging measurements to generate an imaging-index of normal airway structure and function which will be compared with and significantly correlate with MR-guided bronchoscopic sample measurements made before and after 1-/2-years of treatment. The investigators will reveal the pathobiologic relationship between age, asthma duration, clinical remission and imaging normalization with direct comparison to histology-based airway measurements.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Parallel assignment of participants to one of two arms: (1) patients with severe asthma initiating biologic therapy, and (2) healthy volunteers serving as controls. Asthma patients are followed over 2 years to assess clinical, imaging, and histologic responses to biologic treatment. A randomized subset of asthma participants undergoes MRI-guided bronchoscopy to correlate imaging with histopathology.
| Arm | Type | Receives |
|---|---|---|
| Asthma - Biologic Therapy | Experimental | Biological: Biologic TherapyParticipants with severe asthma (GINA 5) who are eligible to begin biologic therapy. Participants will undergo serial assessment with pulmonary imaging (CT, MRI), lung function testing, sputum collection, and symptom questionnaires. A subset of participants (~15%) will be randomized to undergo MRI-guided bronchoscopy with airway sampling at baseline and 2 years. |
| Healthy Control | No intervention | –Age- and sex-matched healthy participants with no history of lung disease. Participants will undergo pulmonary imaging (CT, MRI) and lung function testing at baseline and follow-up for comparison with the asthma group. No therapeutic intervention will be provided. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (17 listed)
- Participant understands study procedures and is willing to participate in the study as indicated by the patient's signature.
- Provision of written, informed consent prior to any study specific procedures.
- Males and females aged 18 to 80 years.
- Either diagnosed with severe asthma (GINA Step 5) and newly eligible for biologic therapy (based on ACQ-5, current treatment, exacerbation history, and blood eosinophils in accordance with approved criteria for omalizumab, mepolizumab, benralizumab, dupilumab, or tezepelumab), or a healthy volunteer with no history of chronic lung disease, matched by age and sex. Healthy participants must have a lifetime combustible tobacco and/or cannabis (including vaping) consumption of ≤5 pack-years.
- Women of childbearing potential (after menarche) must ensure that they are using an effective form of birth control for at least 2 months prior to each imaging visit. Examples of effective birth control include:
Key exclusion criteria (6 listed)
- Participants fulfilling any of the following criteria are not eligible for inclusion in this study:
- Patient has an implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist).
- In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia.
- Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit.
- Participant is unable to perform spirometry or plethysmography maneuvers.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biologic TherapyParticipants with severe asthma (GINA 5) who are eligible to begin biologic therapy. Participants will undergo serial assessment with pulmonary imaging (CT, MRI), lung function testing, sputum collection, and symptom questionnaires. A subset of participants (~15%) will be randomized to undergo MRI-guided bronchoscopy with airway sampling at baseline and 2 years. | Biological | Asthma - Biologic Therapy |
Primary outcome
Determine extent of imaging-based remission in patients with severe asthma following 1 and 2 years of biologic therapy
Time frame: from baseline to year 1 and year 2
Measured using 129Xe ventilation defect percent (VDP)
Measure the extent and timing of clinical remission in patients with severe asthma as measured by changes in spirometry measurements of FEV1 and FVC
Time frame: from baseline to 1 year and 2 years
Measured using forced expiratory volume in 1 second and forced vital capacity
To determine the extent and timing of clinical remission in patients with severe asthma using symptoms scores of ACQ-5 and ACT
Time frame: From baseline to 1 year and 2 years
Measured using changes in asthma control questionnaire and asthma control test
Determine the extent and timing of imaging-based remission in patients with severe asthma using CT airway and vessel morphology
Time frame: From baseline to 1 year and 2 years
Measured using computed tomography (CT) airway and vessel metrics
To determine the extent and timing of clinical remission using the clinical outcome of frequency of asthma exacerbations in patients with severe asthma
Time frame: from baseline to 1 year and 2 years
Measured using the number of asthma exacerbations
To determine the extent and timing of clinical remission of patients with severe asthma using the clinical outcome of OCS use
Time frame: From baseline to 1 year and 2 years
Measured by the frequency of oral corticosteroid usage
Determine the extent and timing of clinical remission in patients with severe asthma as measured by sputum and blood eosinophil counts
Time frame: From baseline to 1 year and 2 years
Measured using blood and sputum eosinophil counts
17 secondary outcomes
Timing and proportion of patients achieving clinical remission after biologic treatment as measured by FEV1 and FVC.
Time frame: From baseline to 1 year and 2 years
To determine the timing and proportion of patients achieving clinical remission as measured by ACQ-5 and ACT questionnaires.
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving clinical remission after biologic treatment using FeNO.
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving clinical remission using DLco.
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving clinical remission after biologic treatment using SGRQ score.
Time frame: From baseline to 1 year and 2 years.
Determine the timing and proportion of patients with severe asthma achieving clinical remission on biologic treatment using AQLQ scores.
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using 129-Xe MRI VDP
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using CT metrics
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using DLco.
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using RV/TLC
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using FRC.
Time frame: From baseline to 1 year and 2 years
Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using changes in VDP
Time frame: from baseline to 12-weeks and 2-years
Determine the relationship between clinical and imaging remission and generate predictive models for their achievement using changes in CT.
Time frame: From baseline to 12-weeks and 2-years
Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using FeNO.
Time frame: From baseline to 12-weeks and 2-years
Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using ACQ-5 and ACT scores.
Time frame: From baseline to 12-weeks and 2-years.
Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using sputum biomarkers.
Time frame: From baseline to 12-weeks and 2-years
Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using exacerbation history.
Time frame: From baseline to 12-weeks and 2-years.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Asthma; Eosinophilic
Active, not recruitingPhase 3
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
Asthma
RecruitingPhase 3
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Active, not recruitingPhase 3
SIM0718 Treatment of Asthma Clinical Study
Asthma; Eosinophilic
RecruitingPhase 2
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
Eosinophilic Asthma
Active, not recruitingPhase 4
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Grace Parraga, PhD principal investigator
Robarts Research Institute, The University of Western Ontario
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Biologic Therapy in people with Asthma; Eosinophilic, run by Western University, Canada at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 31 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Grace Parraga, PhD (519-931-5777 ext. 24197, gparraga@robarts.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Determine extent of imaging-based remission in patients with severe asthma following 1 and 2 years of biologic therapy (time frame: from baseline to year 1 and year 2). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2026.